Please login to the form below

Not currently logged in

Sanofi nominates Bonnie Bassler to board

She has over 20 years of experience
Bonnie Bassler

Sanofi has nominated Bonnie Bassler as an independent member of its board of directors.

Bassler serves as a member of the US National Science Board, as appointed by president Barack Obama, which oversees the National Science Foundation.

Her appointment comes shortly after Sanofi's board sacked CEO Christoper Viehbacher.

Commenting on her nomination, Bassler said: “It is a great honour for me to join Sanofi's board of directors. Sanofi is one of the leading international pharmaceutical companies in the world and I look forward to working closely with members on the board and the company to support Sanofi's mission to develop and introduce innovative therapies.”

Bassler has more than 20 years of experience in the sector and is a Howard Hughes Medical Institute investigator, professor in molecular biology and chair of the department of molecular biology at Princeton University, US.

She also serves on oversight, grant, fellowship and award panels for organisations including the National Academies of Sciences and US National Institutes of Health.

Serge Weinberg, chairman of the board and interim CEO at Sanofi, said: “Professor Bassler's scientific expertise in molecular biology and her great leadership skills makes her an outstanding addition to our board.

“We look forward to her contribution to Sanofi's strategy as we continue to innovate and introduce new medicines and vaccines that can help improve health outcomes.”

27th November 2014


Featured jobs

Subscribe to our email news alerts


Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...